Proteasome function is required for platelet production.
Shi DS et al. J Clin Invest. 2014 Jul 25. pii: 75247. doi: 10.1172/JCI75247. [Epub ahead of print].
Overexpression of CYR61/CCN1 in the multiple myeloma microenvironment is associated with superior survival and prevention of bone disease.
Johnson SK et al. Blood. 2014 Jul 24. pii: blood-2014-02-555813. [Epub ahead of print].
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.
Glavey SV et al. Blood. 2014 Jul 24. pii: blood-2014-03-560862. [Epub ahead of print].
Myeloma cell sensitivity to bortezomib is associated with Dicer1 expression.
Stuhler G et al. Blood. 2014 Jul 24;124(4):657-8. doi: 10.1182/blood-2014-04-571257.
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom Macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Sahin I et al. Am J Hematol. 2014 Jul 24. doi: 10.1002/ajh.23814. [Epub ahead of print].
THE IMMUNOPROTEASOME AS A THERAPEUTIC TARGET FOR HEMATOLOGICAL MALIGNANCIES.
Miller Z et al. Curr Cancer Drug Targets. 2014 Jul 23. [Epub ahead of print].
Relevance of the thyroid hormones-αvβ3 pathway in primary myeloma bone marrow cells and on bortezomib action.
Cohen K et al. Leuk Lymphoma. 2014 Jul 24:1-18. [Epub ahead of print].
Clinical significance of interleukin-22 in multiple myeloma.
Tsirakis G et al. Hematology. 2014 Jul 24. [Epub ahead of print].
Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.
Gkotzamanidou M et al. Br J Cancer. 2014 Jul 22. doi: 10.1038/bjc.2014.410. [Epub ahead of print].
The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.
Hamouda MA et al. Oncotarget. 2014 Jul 9. [Epub ahead of print].
Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia‑inducible factor‑1α and insulin‑like growth factor‑1 mRNA expression.
Rui M, Huang Z et al. Mol Med Rep. 2014 Jul 22. doi: 10.3892/mmr.2014.2407. [Epub ahead of print].
A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance.
Liu Z et al. Blood. 2014 Jul 21. pii: blood-2014-03-557298. [Epub ahead of print].
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.
Quarona V et al. Ann N Y Acad Sci. 2014 Jul 21. doi: 10.1111/nyas.12485. [Epub ahead of print.].
Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
Park B. Biochimie. 2014 Jul 15. pii: S0300-9084(14)00181-3. doi: 10.1016/j.biochi.2014.07.003. [Epub ahead of print].
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.
Zi FM et al. Cancer Biol Ther. 2014 Jul 21;15(10). [Epub ahead of print].
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
Fischer ES et al. Nature. 2014 Jul 16. doi: 10.1038/nature13527. [Epub ahead of print].
Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.
Wen J et al. Int J Cancer. 2014 Jul 15. doi: 10.1002/ijc.29078. [Epub ahead of print].
Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
Ramírez-Labrada A et al. Clin Transl Oncol. 2014 Jul 19. [Epub ahead of print].
The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.
Tagde A et al. Blood Cancer J. 2014 Jul 18;4:e229. doi: 10.1038/bcj.2014.45.
The Alteration and Clinical Significance of Th1/Th2/Th17/Treg Cells in Patients with Multiple Myeloma.
Feng P et al. Inflammation. 2014 Jul 18. [Epub ahead of print].
Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway.
Cao B et al. Sci Rep. 2014 Jul 18;4:5749. doi: 10.1038/srep05749.
Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways.
Pandey MK et al. Exp Hematol. 2014 Jul 14. pii: S0301-472X(14)00530-X. doi: 10.1016/j.exphem.2014.07.261. [Epub ahead of print].
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies.
Caltagirone S et al. Haematologica. 2014 Jul 11. pii: haematol.2014.103853. [Epub ahead of print].
Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation.
Arendt BK et al. Oncotarget. 2014 Jul 3. [Epub ahead of print].
Blood distribution of bortezomib and its kinetics in multiple myeloma patients.
Osawa T et al. Clin Biochem. 2014 Jul 8. pii: S0009-9120(14)00490-1. doi: 10.1016/j.clinbiochem.2014.06.077. [Epub ahead of print].
Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes.
de Bruin G et al. J Med Chem. 2014 Jul 24;57(14):6197-209. doi: 10.1021/jm500716s. Epub 2014 Jul 15.
PRIMA-1Met induces myeloma cell death independently of p53 by impairing the GSH/ROS balance.
Tessoulin B et al. Blood. 2014 Jul 8. pii: blood-2014-01-548800. [Epub ahead of print].
An analysis of the safety profile of proteasome inhibitors for treating various cancers.
Wang H et al. Expert Opin Drug Saf. 2014 Aug;13(8):1043-54. doi: 10.1517/14740338.2014.939953. Epub 2014 Jul 9.
High throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor resistant multiple myeloma.
Stessman HA et al. Leukemia. 2014 Jul 9. doi: 10.1038/leu.2014.214. [Epub ahead of print].
The miR-29 family in hematological malignancies.
Fiserova B et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Jul 4. doi: 10.5507/bp.2014.037. [Epub ahead of print].
Integrative analysis of differential miRNA and functional study of miR-21 by seed-targeting inhibition in multiple myeloma cells in response to berberine.
Luo X et al. BMC Syst Biol. 2014 Jul 7;8(1):82. doi: 10.1186/1752-0509-8-82.
Proteasome-Mediated Processing of Nrf1 Is Essential for Coordinate Induction of All Proteasome Subunits and p97.
Sha Z et al. Curr Biol. 2014 Jul 21;24(14):1573-83. doi: 10.1016/j.cub.2014.06.004. Epub 2014 Jul 3.
Two-step chromatography purification of IgGs possessing sialidase activity from human blood serum.
Kit Y et al. Biomed Chromatogr. 2014 Jul 3. doi: 10.1002/bmc.3283. [Epub ahead of print].
Identifying bias in CCR1 antagonists using radiolabeled binding, receptor internalization, β-arrestin translocation, and chemotaxis assays.
Gilchrist A et al. Br J Pharmacol. 2014 Jul 2. doi: 10.1111/bph.12835. [Epub ahead of print].
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent anti-tumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J et al. Clin Cancer Res. 2014 Jul 1. pii: clincanres.0695.2014. [Epub ahead of print].
Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.
Vandenberg CJ et al. Blood. 2014 Jul 1. pii: blood-2014-04-570770. [Epub ahead of print].
Engineered nanomedicine for myeloma and bone microenvironment targeting.
Swami A et al. Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10287-92. doi: 10.1073/pnas.1401337111. Epub 2014 Jun 30.
MicroRNA-21 and multiple myeloma: small molecule and big function.
Ma J et al. Med Oncol. 2014 Aug;31(8):94. doi: 10.1007/s12032-014-0094-5. Epub 2014 Jul 1.